Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE
Por:
Puente, J, Anido, U, Climent, MA, Gonzalez-Billalabeitia, E, Lainez, N, Lambea, J, Maroto, JP, Mendez-Vidal, MJ, Montesa, A, Rodriguez, A, Zambrana, C, Gonzalez-del-Alba, A
Publicada:
1 may 2020
Resumen:
Objective:
Our aim was to provide practical recommendations on the management of patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel plus androgen-deprivation therapy (ADT) or abiraterone plus ADT.
Methods:
Systematic literature review (SLR), nominal group meeting, and Delphi process. A panel of 12 experts was established who defined the scope, users, and sections of the document. We performed an SLR in order to assess the efficacy and safety of available drugs in patients with mCRPC. Abstracts from the American Society of Oncology and European Society for Medical Oncology meetings were also examined. The results were discussed during an expert meeting in which 14 recommendations were generated. The level of agreement with the recommendations was also tested by 13 additional experts following the Delphi process. Recommendations were voted by means of scores ranging from 0 (total disagreement) to 10 (total agreement). We defined agreement when at least 70% of the experts voted > 7. Next, we assigned a level of evidence and grade to the recommendation using the Oxford Centre for Evidence-based Medicine Levels of Evidence, following which the final document was drafted.
Results:
The literature search did not find any articles meeting the inclusion criteria. Finally, 13 out of 14 recommendations were accepted after two Delphi rounds (two were modified after the first round). They pertain to general and individual case-based treatment recommendations.
Conclusions:
In mCRPC patients who have progressed after docetaxel or abiraterone plus ADT in the metastatic hormone-sensitive prostate cancer setting, these recommendations may support treatment decision-making, due to the lack of evidence or other globally accepted sequencing algorithms.
Filiaciones:
Puente, J:
Hosp Clin San Carlos, CIBERONC, Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Med Oncol Dept, Madrid, Spain
Anido, U:
Complejo Hosp Univ Santiago, Oncol Dept, Santiago De Compostela, Spain
Climent, MA:
IVO, Med Oncol Dept, Valencia, Spain
Gonzalez-Billalabeitia, E:
Univ Murcia, IMIB, Hosp Univ Morales Meseguer, Hematol & Med Oncol Dept, Murcia, Spain
Univ Catolica San Antonio Murcia UCAM, Murcia, Spain
Lainez, N:
Complejo Hosp Navarra, Med Oncol Dept, Pamplona, Spain
Lambea, J:
Hosp Clin Univ Lozano Blesa, Med Oncol Dept, Zaragoza, Spain
Maroto, JP:
Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona, Spain
Mendez-Vidal, MJ:
Hosp Univ Reina Sofia, Med Oncol Dept, Cordoba, Spain
Montesa, A:
Hosp Reg Malaga, Med Oncol Dept, Malaga, Spain
Rodriguez, A:
Hosp Leon, Med Oncol Dept, Leon, Spain
Zambrana, C:
Hosp Univ Infanta Sofia, Med Oncol Dept, San Sebastian De Reyes, Spain
Gonzalez-del-Alba, A:
Hosp Univ Puerta Hierro Majadahonda, Med Ongol Dept, Calle Joaquin Rodrigo 2, Madrid 28222, Spain
Gold, Green Published
|